Spotlight On... Sorrento, Yuhan create a JV for checkpoint drugs; Gene therapy startup Regenxbio grows fast; Hutchison launches PhII in China; and more...

San Diego-based Sorrento Therapeutics ($SRNE) is forming a joint venture with South Korea's Yuhan to develop immune checkpoint antibodies for cancer. Yuhan is seeing ImmuneOncia Therapeutics with a $10 million payment. Release

@FierceBiotech: Merck launches late-stage trials for Humira biosimilar. News | Follow @FierceBiotech

@JohnCFierce: ICYMI: Gilead's latest HIV cocktail wins FDA approval with a blockbuster pedigree. Article | Follow @JohnCFierce

> The Washington Business Journal outlines the fast growth behind the gene therapy company Regenxbio ($RGNX), which now has some 60 staffers. Story

> Hutchison MediPharma Limited launched an open-label Phase II clinical trial to evaluate sulfatinib (HMPL-012) in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer ("DTC") or medullary thyroid cancer ("MTC") in China. The first patient was dosed on March 1, 2016. Release

Medical Device News

@FierceMedDev: Scientists create digital 'magic wand' to improve at-home device cybersecurity. Report | Follow @FierceMedDev

@EmilyWFierce: ICYMI: Voice box maker Atos Medical goes on the chopping block for €1 billion: WSJ. Story | Follow @EmilyWFierce

> Olympus to fork over $646M to DOJ over a bribery scandal in largest-ever medical device settlement. Article

> Smith & Nephew ($SNN) touts its new 3-D printed hip implant. More

> Zimmer ($ZBH) buys Ortho Transmission to better serve amputees using novel surgical approach. News

Pharma News

@FiercePharma: Bayer incoming CEO highlights OTC challenges in China in three-way integration. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: Pressed by reporters, Valeant 'fesses up to SEC investigation. Report | Follow @CarlyHFierce

> Amgen ($AMGN) targets Sandoz's Enbrel biosim with patent infringement suit. Story

> Sanofi ($SNY) having difficulty deciding how, or even if, to divest EU generics biz. Article

> U.K. cost watchdogs snub key J&J ($JNJ) med Imbruvica on first go-around. More

Biotech Research News

> Stanford researchers show glucose-binging immune cells central to coronary artery disease. More

> Clearing inflammatory cells improves memory in a mouse model for Alzheimer's. Story

> Texas Tech team experiments with CRISPR/Cas9 upgrade. Item

> Single monoclonal antibody shows promise in pre-clinical Ebola virus disease. Report

> Molecular 'brake' curbs inflammation, could combat aging. Article

Pharma Marketing News

> Amgen hits Sandoz with patent infringement suit over Enbrel biosim. Item

> Dancing bladders and football-helmeted toenails have FDA questioning cartoons in DTC ads. Report

> Free speech crops up in another off-label marketing legal victory for industry. Article

> Don't give up on biosim Copaxone, despite Teva's ($TEVA) aggressive brand defense: Momenta CEO. More

> Talk show host Dr. Phil has a new subject: AstraZeneca's ($AZN) Bydureon. Story

Vaccines News

> U.K. rejects petition demanding meningitis B vaccine for all children. More

> Novavax ($NVAX) explores Zika vaccine R&D effort as the virus continues to spread. Report

> Seqirus to build new U.K. manufacturing outpost. Item

> U.S. Army, GSK's ($GSK) P. vivax malaria vaccine fails to protect in an early trial. Story

> New South Korean study could help direct MERS vaccine development. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.